chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I actually had a slight cough and irritation in my throat and didn't think much of it. My husband was more sick than me, and he wanted to go to urgent care. I started to have the same symptoms as he did so I knew something was up. I felt flu-like symptoms and was very uncomfortable. I had body aches, chills. I took Tylenol. This lasted about 3 days. It was mild for me.
This spontaneous report was received from a licensed vocational nurse concerning an unspecified number of patients of unknown age and gender. The patients' pertinent medical history, concurrent conditions, concomitant therapies, drug reactions or allergies were not reported. On an unknown date the patients were vaccinated with improperly stored PNEUMOVAX23 lot # K008409, expiration date 04-MAR-2016, (dose, dose number, route and anatomical location were unspecified). No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Severe headache, severe fatigue and body aches, vomiting, diarrhea. Started 6hrs after shot. Now is 52hrs later and still having symptoms.
This is a spontaneous report from a contactable other health care professional (patient self-reported). A 29-year-old female patient (who was not pregnant at the time of vaccination), received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number; EL3247 and expiry date was not provided), via an unspecified route of administration, at arm Right on 26Jan2021, at a single dose for COVID-19 immunization, in Workplace clinic. Patient's medical history was reported as none and concomitant medications were not reported. Patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not received any other vaccines within 2 weeks of vaccination of COVID vaccine. On same day (26Jan2021), the patient experienced soreness in right arm and it is persistent after 24hours. Patient was not received any treatment for the event. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Seriousness of the event was reported as non serious. Outcome of the event was recovering.
Redness, soreness, swelling, itching at injection site - began second day - rear upper left arm - grew from armpit to below elbow - itching on 8th day only - redness/swelling lasted two weeks - no other symptoms.
DTaP, IPV and MMR administered on 8/12, 8/14 awoke with generalized urticaria-including 2x3cm oral area at injection sites of DTaP and IPV (together on left arm) treated with Benadryl and Zyrtec.
Arm  extremely swollen; A spontaneous report was received from a female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced arm extremely swollen.  The patient's medical history was not provided. No relevant concomitant medications were reported.   On 29 Dec 2020, about a week prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.   She had no reactions but now, her arm was extremely swollen a week later.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The event arm extremely swollen was unknown.  The reporter did not provide an assessment for the event arm extremely swollen.; Reporter's Comments: This case concerns a female patient of unknown age. The patient's medical history was not provided. The patient experienced an event of extremely swollen arm. The event occurred a week after the first dose of mRNA-1273. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Administered patient vaccines; Flu shot on left and Pneumo on right. Started to prepare to draw labs and patient complained of dizziness. Asked patient to breathe through nose and out mouth and continued talking to patient. Offered to have him lay down, he declined. He did ask for water. I asked another medical assistant to stay with him while I retrieved a glass of water and brought a RN back with me. After some water, he stated he felt a little better. I checked BP which was 94/68. RN obtained pulse. At this time patient again stated he was dizzy and he started to pass out. A NP came in and code was called. Patient started vomiting as we were sliding him to floor on left side. AED was retrieved but patient was breathing. NP at side as well as nurse.Ambulance was called and patient starting coming to. Patient was alert and knew where he was and what happened. Ambulance came and took over. Personal effects: Cell phone and glasses given to EMT.
Scattered popular-vesicular eruptions on face, upper extremities. Faded appearing papules on lower extremities; Solitary erythematous popular lesion on left palm.
This spontaneous report was received from a physician and from a support services director via company representatives and refers to a patient of an unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 02-NOV-2015, the patient was vaccinated with a dose of an improperly stored GARDASIL 9 (strength: 0.5 ml) lot # L014198 and expiration date: 05-SEP-2017 (dose, anatomical location and route of administration were not reported). No adverse effects were reported. The dose of the vaccine was exposed to different temperature excursions (date unspecified): lasting for 48, and 80 hours, with the lowest recorded temperature of 33, and 34 degrees Fahrenheit (0.55, and 1.11 degrees Celsius) respectively. The vaccine was stored in a refrigerator. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
This is a spontaneous report obtained from a non-contactable pharmacist. A female patient of an unspecified age, race and ethnicity, received, PREVNAR 13 single dose, on an unknown date, for immunization. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced red spots and it hurt too. Clinical outcome was unknown at time of this report. No follow up attempts possible. No further information expected.
Pt recvd vax & exp fever, fatigue, flu-like sx, joint pain, & arthritic pain which lasted 72 hrs;
Slightly itchy small pimple like rash on legs, torso, chest and arms.
No problem at injection site.  By 2-3pm, Thursday, some pain/soreness and slight swelling  in left tricept.  worse through Friday into Saturday, particularly near elbow,  Pain, soreness, swelling  began to decline Sunday, nearly gone by late Sunday.  Friday at~3am, woke for bathroom visit.  Felt dizzy, lightheaded in bathroom, needed to stop and grab support.  Headed back to bedroom, felt dizzy again and apparently passed out on floor for about an hour or less.  Woke in a cold sweat though I otherwise felt fine.  Went to bed and slept through the rest of the night.  No more collapsing, though I did feel a bit tired and "out of sorts" most of Friday and Saturday.
This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a adult male patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than year after receiving SHINGRIX, the patient experienced facial swelling. On an unknown date, the outcome of the facial swelling was unknown. It was unknown if the reporter considered the facial swelling to be related to SHINGRIX. Additional details were provided as follows: This case was reported by a pharmacy intern. The age at vaccination was not reported. The caller declined to provide further details or identifies without getting permission from patient involved. Limited report was filed. This case was 1 of the 3 linked cases, reported by the same reporter.
she just had soreness on her arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 55 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "she just had soreness on her arm". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient started to vomit, got pale, diaphoretic, and passed out for a few seconds. Epinephrine 0.3 mg IM was given and her blood pressure was low. 911 was called and she was transported to the nearest Emergency department.
HEAVINESS IN CHEST; DIZZY/FEELING LIKE SHE WOULD PASS OUT; COUGHING; FEVER; TIREDNESS; MUSCLE ACHES; PROFUSE SWEATING; NOT FEELING WELL; OUT OF WORK SICK; FIBROMYALGIA WORSENED PAIN; This spontaneous report received from a patient concerned a 50 year old female. The patient's height, and weight were not reported. The patient's past medical history included covid-19 disease, ear ringing, headache, fatigue, muscle aches, fibromyalgia pain, and celiac disease, and concurrent conditions included alcohol consumption, and other pre-existing medical conditions included patient felt fullness, tried lyrica, flu shot 2020 and the patient eats gluten free. The patient was previously treated with erythromycin. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805025, and batch number: 1805025 expiry: UNKNOWN) dose was not reported, administered on 10-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced fibromyalgia worsened pain. On MAR-2021, the subject experienced not feeling well. On MAR-2021, the subject experienced out of work sick. On 11-MAR-2021, the subject experienced muscle aches. On 11-MAR-2021, the subject experienced profuse sweating. On 11-MAR-2021, the subject experienced tiredness. On 11-MAR-2021 01:00, the subject experienced fever. On 13-MAR-2021, the subject experienced coughing. On 14-MAR-2021, the subject experienced heaviness in chest. On 14-MAR-2021, the subject experienced dizzy/feeling like she would pass out. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from muscle aches, profuse sweating, fever, and tiredness on 12-MAR-2021, was recovering from coughing, had not recovered from heaviness in chest, and dizzy/feeling like she would pass out, and the outcome of not feeling well, fibromyalgia worsened pain and out of work sick was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as case assessed as non-serious.
clots were coming out; nose bleed; blood pressure went up; This is a spontaneous report from a contactable consumer (classmate's sister). This is the second of two reports. A 62-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection) via an unspecified route of administration on an unspecified date (at an unspecified age) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection) via an unspecified route of administration on an unspecified date (at an unspecified age) as a single dose for COVID-19 immunization. On an unspecified date (almost a month after receiving the second COVID-19 vaccine) the patient experienced clots were coming out, nosebleed and blood pressure went up. The reporter called to report that she had received a phone call from an old classmate, who had a sister, who experienced the same reaction after getting the Pfizer vaccine. This patient experienced the same nosebleeds after the COVID-19 vaccine. This person's nosebleeds started almost a month after she received the second dose of the COVID-19 vaccine. That was when the reporter started trying to figure out where these nosebleeds were coming from. She did not have any further information on the person that she mentioned. The clinical outcomes of the events clots were coming out, nosebleed and blood pressure went up were unknown.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021476256 same reporter/drug/event, different patient
Immediately arm started itching then redness and fever began. Called doctor 5 days later who recommended BENADRYL. BENADRYL controlled itching but redness and heat continued. On 11/14 went to ER confirmed that it was a reaction and gave her ranitidine and prednisone; seems to have helped but it made her hyper - a side effect. ER doctor noticed that redness spreading down arm. Today will call doctor to follow-up and see if antibiotic required.
Patient waited for 15 minutes after shot, felt fine, walked out to waiting room and felt dizzy, brought her back in and gave her juice and crackers, took her blood pressure, waited 15 minutes, took her blood pressure again.  She felt fine, and left.  Called in this morning, is dizzy, has a fever and pain at the injection site, as well as a headache.  Patient's father has a virus, could be coincidental.
This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six  patients received the vaccine in question) and EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six patients received the vaccine in question) in a 55-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination. No Medical History information was reported. On 09-Mar-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 09-Mar-2022, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six patients received the vaccine in question) and EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six patients received the vaccine in question). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six patients received the vaccine in question) and EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine which has undergone multiple temperature excursions. Twenty six patients received the vaccine in question) outcome was unknown. The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown. For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments. The Nurse reports no adverse reactions or side effects to the Moderna Covid-19 vaccine. No concomitant medication were given. No treatment information were given. Date vial moved from freezer to refrigerator. 3-MAR-2022.
Pt hospitalized for 2 days p/Hepatitis shot; MD stated poss reaction from shot; also has ulcer c/o nausea, t102, pain in abdo & body aching; also had some diarrhea;
Patient had immediate reaction: he passed out, had a seizure, sweated. Patient stated that he had not eaten; we provided a donut and water and put a fan on him. We observed him directly for 30 minutes.
2nd dose administered beyond 30 day use; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (2nd dose administered beyond 30 day use) in a 21-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (2nd dose administered beyond 30 day use). On 22-Oct-2021, EXPIRED PRODUCT ADMINISTERED (2nd dose administered beyond 30 day use) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   2 vials were taken out of freezer on 08-Sep-2021 and first dose was given to 1 patient, second dose was administered to 9 patients, third dose was given to 2 immunocompromised patient. No temperature excursion was reported.  No concomitant medication was reported by reporter. No treatment medication was reported by reporter.
Pt's wife reported that pt has been experiencing intense upper arm pain persistently since the injection. At first they thought it was normal muscle soreness but became concerned when the discomfort continued over a month after the injection. The sensation can be described as pain, burning, soreness, and reduced range of motion (cannot raise arm completely over head). Pt's wife is a physical therapist and has been performing physical therapy on the arm nightly, which helps temporarily but has not resolved the issue. Pt also takes ibuprofen at bedtime to help him sleep, which is minimally effective.  The injection site is still visible, but is not red or rashy in any way. The pt also reports that he had an itchy rash on the left side of his trunk shortly after the vaccine, which self-resolved. They did not provide dates. His injection was in his right deltoid. At this point they are considering pursuing further medical testing/imaging to determine an explanation for the pain and decide treatment options.
Mother phoned on 04/05 am stating that the her child developed "rash" at 18:00 on 04/04 on neck, ear, "red" also on face but less red, legs light pink. Denies itching or fever or any other symptoms. States saw ER at 22:00 and was given Hydroxyzine. Mother reports that rash gone after 2nd dose of medication.
The following morning dark coloration along with puffiness appeared under both of my eyes -- it seems like a slight allergic reaction.
Tenderness and swelling at injection site; Tenderness and swelling at injection site; neck swelling; heat to neck; nauseous; This is a spontaneous report from a contactable nurse via Pfizer Sales Representative. A 18-year-old female patient received meningococcal group b rlp2086 (TRUMENBA, lot number: CW2843, strength: 0.5 ml) via an unspecified route of administration on 11Aug2020 at single dose for immunisation. Medical history and concomitant medications were unknown. On 11Aug2020, the patient experienced tenderness and swelling at injection site, neck swelling and heat to neck a few hours later, nauseous. No other vaccine was given. Event took place after use of product. Outcome of all events was unknown.   No follow-up attempts are needed. No further information is expected.
Information has been received from a nurse practitioner concerning a 12 month old male with eczema and egg allergy who on 11-JUL-2008 was vaccinated subcutaneously with a 0.5ml dose of VARIVAX (Oka/Merck) in the right thigh(lot # 659456/1912U). Secondary suspect therapy included MMR II. Other concomitant therapy included PREVNAR and HAVRIX. On 13-JUL-2008 or 14-JUL-2008 the patient developed a rash on his trunk. At the time of this report, the patient's a rash on his trunk persisted. Medical attention was ought via office visit. No product quality complaint was involved. Additional information has been requested.
4-15-09 noticed area red, swollen, warm in am.  Saw doc, gave her TYLENOL.  By 11 AM continued to spread.  Saw doc again.  Diagnosed as cellulitis.  Gave 1 g ROCEPHIN IM, 4 mg DECADRON IM, 80 mg DEPONEDROL IM and PO BENADRYL 50 mg q6n as needed.  By 9-17-09 pt had completely recovered.
Body aches; fever; This spontaneous case was reported by a patient and describes the occurrence of MYALGIA (Body aches) and PYREXIA (fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (Body aches) and PYREXIA (fever). At the time of the report, MYALGIA (Body aches) and PYREXIA (fever) had resolved.            No concomitant medications were reported. No Treatment medications were reported.   This case was linked to MOD-2021-028189 (Patient Link).
This case was reported by a nurse via call center representative and described the occurrence of cellulitis in a adult female patient who received FLUARIX. On an unknown date, the patient received FLUARIX. On an unknown date, 10 min after receiving FLUARIX, the patient experienced cellulitis (serious criteria GSK medically significant), redness and skin warm. The patient was treated with ibuprofen, ALLEGRA and medication unknown, medication unknown (Ice Pack (Nos)). On an unknown date, the outcome of the cellulitis, redness and skin warm were recovered/resolved. It was unknown if the reporter considered the cellulitis, redness and skin warm to be related to FLUARIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received the vaccine on unknown arm. The reporter stated that the patient developed a reaction distal to the injection site, but in the injected arm. She stated the reaction looked like cellulitis because it was red and hot. The event went away after about a day and the patient felt better. The patient requested that medical information called her about using in pregnant women. The patient stated that she had read the package label and was aware of the center for disease control (CDC) recommendation, but was looking for any additional information.
Blue-red discoloration, ecchymosis, approx. 3 in. in diameter. Swelling and tenderness present.
DRILL/ MONDAY AFTER/ SO FATIGUED (SLEPT ENTIRE DAY,MISSED WORK)                     ENTIRE WEEK/ACHE ALL OVER, DON'T FEEL GOOD, EASILY AGITATED, MOODY, NO ENERGY, UPSET STOMACH.
Started with sore arm redness pain at injection site. Left arm numbness after injections and fever started 5 PM (undocumented) per patient report, vomiting occurred at 1:30 on 10/24/17. Symptoms resolved 10/25/17 midday. Rest and fluids by mouth for treatment. Report of illness by phone call and follow up by phone call.
I told the people who gave me the injection that I was allergic to dairy.  I was suppose to get  a Pfizer vaccine because it doesn't have dairy in it.  On my card, they gave me a Moderna injection.